Walleye Capital LLC Purchases 71,127 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN)

Walleye Capital LLC raised its position in Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 101.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 141,127 shares of the company's stock after buying an additional 71,127 shares during the quarter. Walleye Capital LLC owned 0.25% of Design Therapeutics worth $871,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in DSGN. American Century Companies Inc. increased its position in Design Therapeutics by 19.9% during the fourth quarter. American Century Companies Inc. now owns 39,115 shares of the company's stock worth $241,000 after acquiring an additional 6,481 shares during the period. Geode Capital Management LLC raised its position in shares of Design Therapeutics by 7.1% in the third quarter. Geode Capital Management LLC now owns 758,550 shares of the company's stock valued at $4,081,000 after buying an additional 50,579 shares in the last quarter. Barclays PLC boosted its stake in shares of Design Therapeutics by 34.2% in the third quarter. Barclays PLC now owns 96,635 shares of the company's stock valued at $520,000 after buying an additional 24,602 shares during the period. JPMorgan Chase & Co. grew its position in Design Therapeutics by 186.9% during the third quarter. JPMorgan Chase & Co. now owns 40,687 shares of the company's stock worth $219,000 after buying an additional 26,503 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Design Therapeutics by 2.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 264,675 shares of the company's stock worth $1,633,000 after acquiring an additional 7,243 shares during the period. Institutional investors own 56.64% of the company's stock.

Design Therapeutics Stock Down 8.5 %

Shares of NASDAQ:DSGN traded down $0.36 during trading on Friday, reaching $3.88. 137,741 shares of the company traded hands, compared to its average volume of 202,377. The firm has a market capitalization of $220.24 million, a PE ratio of -4.56 and a beta of 1.82. Design Therapeutics, Inc. has a 52 week low of $2.60 and a 52 week high of $7.77. The company's 50 day moving average is $4.18 and its two-hundred day moving average is $5.05.

Design Therapeutics (NASDAQ:DSGN - Get Free Report) last posted its quarterly earnings data on Monday, March 10th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.04. As a group, research analysts anticipate that Design Therapeutics, Inc. will post -0.91 EPS for the current year.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.